BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV) July 8, 2025 Read the Medium Article from our CEO, Jared Bauer, about the Urgent Need to Fight RSV Globally. Salt Lake City, UT (Business Wire) — Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and…